ADMA Biologics to Announce Q1 2024 Financial Results on May 9, 2024

ADMA Biologics, Inc. (Nasdaq: ADMA) announced that it will disclose its financial results for the first quarter of 2024 on May 9, 2024, after the U.S. financial markets close. Following this announcement, the management team will conduct a live conference call and audio webcast at 4:30 p.m. ET to discuss the financial performance and other company updates. Participants are required to register online to receive the necessary dial-in numbers and a unique PIN for the call, and it is recommended to join the call approximately 10 minutes before the event starts. For those who do not wish to ask questions, a live webcast will be available, and a replay will be accessible under the “Events & Webcasts” section in the investor section of ADMA’s website.

ADMA Biologics is a commercial biopharmaceutical company focused on the manufacturing, marketing, and development of specialty biologics. These biologics are designed for immunodeficient patients at risk of infections and for those at risk of specific infectious diseases. The company has three FDA-approved plasma-derived biologics: BIVIGAM®, ASCENIV™, and NABI-HB®.

BIVIGAM® is an immune globulin intravenous that treats primary humoral immunodeficiency (PI). ASCENIV™ is another immune globulin intravenous product, specifically a 10% liquid formulation, also used in the treatment of PI. NABI-HB® is a hepatitis B immune globulin that provides enhanced immunity against the hepatitis B virus.

ADMA Biologics operates an FDA-licensed plasma fractionation and purification facility in Boca Raton, Florida, where it manufactures its immune globulin products. Additionally, through its ADMA BioCenters subsidiary, the company functions as an FDA-approved source plasma collector within the United States, supplying the blood plasma necessary for its product manufacturing.

The mission of ADMA Biologics is centered on the production, marketing, and development of specialty biologics and human immune globulins. These products are targeted at niche patient populations for the prevention and treatment of specific infectious diseases, as well as for the management of immune-compromised patients who might have underlying immune deficiencies or be compromised for other medical reasons.

How to obtain the latest research advancements in the field of biopharmaceuticals?

In the Synapse database, you can keep abreast of the latest research and development advances in drugs, targets, indications, organizations, etc., anywhere and anytime, on a daily or weekly basis. Click on the image below to embark on a brand new journey of drug discovery!